RA Capital Management 13F holdings, Q2 2016
Holdings as of June 30, 2016 · filings on SEC EDGAR · latest filing →
RA Capital Management disclosed 32 US equity positions worth $722.2m in its Q2 2016 13F filing. The largest position was WVE at 20.3% of the reported book, followed by ACHILLION PHARMACEUTICALS INC and AXOVANT SCIENCES LTD. Against the Q1 2016 filing, it opened 2 new positions, added to 3 and reduced 9 among the top 32 holdings.
What did RA Capital Management own in Q2 2016? Top 32 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2016 |
|---|---|---|---|---|---|---|---|
| 1 | WVE WAVE LIFE SCIENCES LTD | Healthcare | 20.3% | $146.7m | 7,088,651 | 0% | held |
| 2 | ACHILLION PHARMACEUTICALS INC | 13.0% | $93.9m | 12,033,220 | 0% | held | |
| 3 | AXOVANT SCIENCES LTD | 8.9% | $64.2m | 5,000,000 | 0% | held | |
| 4 | AVEXIS INC | 7.1% | $50.9m | 1,339,382 | -2% | reduced | |
| 5 | ACRS ACLARIS THERAPEUTICS INC | Healthcare | 6.7% | $48.5m | 2,627,719 | 0% | held |
| 6 | NKTR NEKTAR THERAPEUTICS | Healthcare | 6.4% | $45.9m | 3,224,854 | 1% | added |
| 7 | ASND ASCENDIS PHARMA A S | Healthcare | 6.3% | $45.3m | 3,412,857 | 58% | added |
| 8 | TGTX TG THERAPEUTICS INC | Healthcare | 3.8% | $27.5m | 4,531,714 | 0% | held |
| 9 | ARDX ARDELYX INC | Healthcare | 2.8% | $20.2m | 2,312,243 | 1% | added |
| 10 | ZOGENIX INC | 2.7% | $19.7m | 2,451,237 | 0% | held | |
| 11 | VITAE PHARMACEUTICALS INC | 2.4% | $17.0m | 1,575,000 | 0% | held | |
| 12 | AIMT AIMMUNE THERAPEUTICS INC | 1.9% | $14.0m | 1,292,940 | 0% | held | |
| 13 | ALCOBRA LTD | 1.9% | $13.6m | 3,032,911 | 0% | held | |
| 14 | PROTEON THERAPEUTICS INC | 1.8% | $13.1m | 1,626,931 | 0% | held | |
| 15 | AQUINOX PHARMACEUTICALS INC | 1.6% | $11.2m | 1,691,977 | 0% | held | |
| 16 | STRONGBRIDGE BIOPHARMA PLC | 1.5% | $10.6m | 2,675,338 | -1% | reduced | |
| 17 | NTRA NATERA INC | Healthcare | 1.3% | $9.5m | 783,520 | 0% | held |
| 18 | DIMENSION THERAPEUTICS INC | 1.3% | $9.3m | 1,548,033 | 0% | held | |
| 19 | BCRX BIOCRYST PHARMACEUTICALS | Healthcare | 1.2% | $8.5m | 2,989,795 | 0% | held |
| 20 | DICERNA PHARMACEUTICALS INC | 1.0% | $7.3m | 2,428,571 | 0% | held | |
| 21 | SGMOQ SANGAMO BIOSCIENCES INC | Healthcare | 0.9% | $6.8m | 1,165,938 | -47% | reduced |
| 22 | AGILE THERAPEUTICS INC | 0.9% | $6.5m | 853,151 | -20% | reduced | |
| 23 | TENX TENAX THERAPEUTICS INC | 0.8% | $6.1m | 2,389,700 | 0% | held | |
| 24 | EIGER BIOPHARMACEUTICALS INC | 0.8% | $5.8m | 291,700 | 0% | held | |
| 25 | ONC BEIGENE LTD | Healthcare | 0.7% | $5.1m | 170,000 | 0% | held |
| 26 | CIDARA THERAPEUTICS INC | 0.6% | $4.2m | 410,809 | -65% | reduced | |
| 27 | AKTX AKARI THERAPEUTICS PLC | 0.4% | $3.2m | 234,240 | -9% | reduced | |
| 28 | AEGLEA BIOTHERAPEUTICS INC | 0.4% | $2.5m | 521,550 | – | new | |
| 29 | MERUS N V | 0.3% | $1.9m | 237,599 | – | new | |
| 30 | ZYNERBA PHARMACEUTICALS INC | 0.2% | $1.7m | 253,468 | -50% | reduced | |
| 31 | ARCA BIOPHARMA INC | 0.2% | $1.6m | 562,693 | -28% | reduced | |
| 32 | PRONAI THERAPEUTICS INC | 0.0% | $59.0k | 29,719 | -95% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.